[go: up one dir, main page]

CL2014000289A1 - Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. - Google Patents

Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.

Info

Publication number
CL2014000289A1
CL2014000289A1 CL2014000289A CL2014000289A CL2014000289A1 CL 2014000289 A1 CL2014000289 A1 CL 2014000289A1 CL 2014000289 A CL2014000289 A CL 2014000289A CL 2014000289 A CL2014000289 A CL 2014000289A CL 2014000289 A1 CL2014000289 A1 CL 2014000289A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
compounds
naphthyridones
dihydro
inhibitors
Prior art date
Application number
CL2014000289A
Other languages
English (en)
Inventor
Jeróme Emile Georges Guillemont
David Francis Alain Lancois
Magali Madeleine Simone Motte
Anil Koul
Wendy Mia Albert Balemans
Eric Pierre Alexandre Arnoult
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000289(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of CL2014000289A1 publication Critical patent/CL2014000289A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2014000289A 2011-08-10 2014-02-05 Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. CL2014000289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10

Publications (1)

Publication Number Publication Date
CL2014000289A1 true CL2014000289A1 (es) 2014-07-11

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000289A CL2014000289A1 (es) 2011-08-10 2014-02-05 Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.

Country Status (24)

Country Link
US (7) US8906923B2 (es)
EP (1) EP2742045B1 (es)
JP (2) JP5921687B2 (es)
KR (1) KR101996862B1 (es)
CN (2) CN105461684B (es)
AR (1) AR087508A1 (es)
AU (1) AU2012293621B2 (es)
BR (1) BR112014003063B1 (es)
CA (1) CA2842518C (es)
CL (1) CL2014000289A1 (es)
DK (1) DK2742045T3 (es)
EA (1) EA201490438A1 (es)
ES (1) ES2721658T3 (es)
HU (1) HUE042978T2 (es)
IL (1) IL230549A (es)
JO (1) JO3611B1 (es)
MX (1) MX348128B (es)
PE (1) PE20141410A1 (es)
PH (1) PH12014500317A1 (es)
TR (1) TR201905537T4 (es)
TW (1) TWI568731B (es)
UA (1) UA111210C2 (es)
UY (1) UY34253A (es)
WO (1) WO2013021054A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
BR112014002958B1 (pt) 2011-08-10 2020-10-06 Janssen Sciences Ireland Uc 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso
US9315522B2 (en) * 2012-08-10 2016-04-19 Janssen Sciences Ireland Uc Antibacterial compounds
AR097794A1 (es) 2013-09-26 2016-04-13 Mnemosyne Pharmaceuticals Inc Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
SI3448859T1 (sl) 2017-03-20 2020-02-28 Forma Therapeutics, Inc. Sestavki pirolopirola kot aktivatorji piruvat kinaze (PKR)
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
KR102872166B1 (ko) 2018-11-12 2025-10-15 데비오팜 인터네셔날 에스 에이 항생제 화합물, 이의 제조 방법, 이를 포함하는 약학적 조성물 및 그 용도
BR112022004376A2 (pt) 2019-09-19 2022-06-07 Forma Therapeutics Inc Ativação de piruvato quinase r
AU2022236404A1 (en) * 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
ES2270874T3 (es) 1999-10-08 2007-04-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
KR101299399B1 (ko) * 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
EP2501693B1 (en) * 2009-11-18 2014-09-17 FAB Pharma SAS Aza heterocyclic acrylamides and their use as bactericides
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Hivの治療のための組成物および方法
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
EA038317B1 (ru) 2011-08-10 2021-08-09 Янссен Сайенсиз Айрлэнд Юси Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
BR112014002958B1 (pt) 2011-08-10 2020-10-06 Janssen Sciences Ireland Uc 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso

Also Published As

Publication number Publication date
US20190194194A1 (en) 2019-06-27
DK2742045T3 (en) 2019-04-23
UA111210C2 (uk) 2016-04-11
KR20140072034A (ko) 2014-06-12
US9290493B2 (en) 2016-03-22
US10526331B2 (en) 2020-01-07
AU2012293621A1 (en) 2014-02-13
US9617262B2 (en) 2017-04-11
CN103874698A (zh) 2014-06-18
IL230549A0 (en) 2014-03-31
WO2013021054A1 (en) 2013-02-14
EP2742045B1 (en) 2019-01-23
BR112014003063B1 (pt) 2020-11-17
AU2012293621B2 (en) 2016-07-21
EA201490438A1 (ru) 2014-06-30
HUE042978T2 (hu) 2019-07-29
IL230549A (en) 2017-07-31
ES2721658T3 (es) 2019-08-02
CA2842518C (en) 2019-07-23
US20180105525A1 (en) 2018-04-19
CA2842518A1 (en) 2013-02-14
TWI568731B (zh) 2017-02-01
PH12014500317A1 (en) 2014-04-14
AR087508A1 (es) 2014-03-26
CN105461684A (zh) 2016-04-06
MX2014001600A (es) 2014-04-25
KR101996862B1 (ko) 2019-07-05
JP2016190843A (ja) 2016-11-10
NZ620212A (en) 2015-10-30
US10501463B2 (en) 2019-12-10
TR201905537T4 (tr) 2019-05-21
BR112014003063A2 (pt) 2017-02-21
US20140171451A1 (en) 2014-06-19
CN103874698B (zh) 2016-03-23
JP2014531404A (ja) 2014-11-27
CN105461684B (zh) 2018-09-25
US20190084982A1 (en) 2019-03-21
US20170174683A1 (en) 2017-06-22
EP2742045A1 (en) 2014-06-18
US9884864B2 (en) 2018-02-06
JO3611B1 (ar) 2020-08-27
US20150080413A1 (en) 2015-03-19
MX348128B (es) 2017-05-26
US8906923B2 (en) 2014-12-09
US20160194324A1 (en) 2016-07-07
US10155759B2 (en) 2018-12-18
UY34253A (es) 2013-02-28
HK1199243A1 (zh) 2015-06-26
HK1223352A1 (zh) 2017-07-28
JP5921687B2 (ja) 2016-05-24
PE20141410A1 (es) 2014-10-13
TW201313714A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
CL2014000289A1 (es) Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2013001282A1 (es) Sal succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico; composicion farmaceutica que la comprende y procesos para su preparacion.
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
CL2013001713A1 (es) Compuestos derivados de bemzimidazol, proceso para prepar dichos compuestos; composicion farmaceutica que los comprende; proceso para preparar esta composicion farmaceutica; y su uso para inhibir la replicacion del visus sincicial respiratorio (rsv).
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112014003681A2 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
PH12015500260A1 (en) Neprilysin inhibitors
ES2603028T8 (es) Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112014030743A2 (pt) inibidores de neprilisina
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014004310A2 (pt) composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
BR112013032876A2 (pt) uso de formulações, e, método para fertilizar plantas
GT201400090A (es) 2-tiopirimidinonas
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
EP2738153A4 (en) PROCESS FOR PREPARING 3,3-DIMETHYL-BUTYRALDEHYDE